SCHEMBL5549445

SCHEMBL5549445

C[C@@H](O)[C@@H](C)C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL55047 1.00
SCHEMBL791249 1.00
SCHEMBL1041254 1.00
SCHEMBL2107037 1.00
SCHEMBL55048 1.00
SCHEMBL2932270 1.00
SCHEMBL3518225 1.00
SCHEMBL2687210 1.00
Ammonia Solution, Strong SCHEMBL2340361 0.97
SCHEMBL28118146 0.97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3019624-B1 BIOMARKERS OF AUTISM SPECTRUM DISORDER STEMINA BIOMARKER DISCOVERY INC (US) 2020-09-16 EP disclosed
US-20190072569-A1 BIOMARKERS OF AUTISM SPECTRUM DISORDER STEMINA BIOMARKER DISCOVERY, INC. 2019-03-07 US disclosed
US-10060932-B2 Biomarkers of autism spectrum disorder STEMINA BIOMARKER DISCOVERY, INC. (US) 2018-08-28 US disclosed
US-20170242005-A1 METHOD AND KIT FOR DETECTION OF MYCOBACTERIA BANGOR UNIVERSITY (GB) 2017-08-24 US disclosed
US-20160169915-A1 BIOMARKERS OF AUTISM SPECTRUM DISORDER STEMINA BIOMARKER DISCOVERY, INC. 2016-06-16 US disclosed
US-9062028-B2 Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2015-06-23 US disclosed
US-8889894-B2 Compounds for use in therapy BANGOR UNIVERSITY (GB) 2014-11-18 US disclosed
US-8728515-B2 Adjuvants for use in vaccination BANGOR UNIVERSITY (GB) 2014-05-20 US disclosed
US-20140080788-A1 NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2014-03-20 US disclosed
US-20070197585-A1 Use of cysteinyl leukotriene 2 receptor antagonists EVANS JILLY 2007-08-23 US disclosed
WO-2007062664-A2 ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES NUEVOLUTION A/S (DK) 2007-06-07 WO disclosed
EP-1727533-A1 USE OF CYSTEINYL LEUKOTRIENE 2 RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2006-12-06 EP disclosed
WO-2005082346-A1 USE OF CYSTEINYL LEUKOTRIENE 2 RECEPTOR ANTAGONISTS MERCK & CO, INC. (US) 2005-09-09 WO disclosed
US-20030083225-A1 Organolipic substance NATIONAL BANK OF CANADA (CA) 2003-05-01 US disclosed
EP-0774452-B1 Optically active compounds having plural chiral centers and the production thereof CHISSO CORP (JP) 2000-01-26 EP disclosed
EP-0428392-B1 Processes for the preparation of optically active compounds having plural chiral centers CHISSO CORP (JP) 1998-05-27 EP disclosed
EP-0774452-A1 Optically active compounds having plural chiral centers and the production thereof Chisso Corporation (JP) 1997-05-21 EP disclosed
US-5574182-A HYDROLYSING 3-HYDROXYCARBOXYLIC ACID, CYCLIZING ESTER TO FORM 1,3-DIOXAN-4-ONE, DECYCLIZATION AND ESTERIFICATION CHISSO CORPORATION (JP) 1996-11-12 US disclosed
US-5348870-A Using hydrolase to effect ester interchange and resolution, then alcoholysis or hydrolysis and dehydration with cyclization and crystallization CHISSO CORPORATION (JP) 1994-09-20 US disclosed
EP-0428392-A2 Optically active compounds having plural chiral centers and the production thereof Chisso Corporation (JP) 1991-05-22 EP disclosed